Cell-Penetrating Peptides in Cancer Targeting

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 3, Issue , 2011, Pages 1187-1217

  Kurrikoff, Kaido ^a   Suhorut, Julia ^b   Langel, Ülo ^c  

^a UNIVERSITY OF TARTU   (Estonia)

^b Estonian Biocenter ^*  (Estonia)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Cell penetrating peptides; Drug delivery; Homing peptide; Peptide vector; Tumor targeting

Indexed keywords

EID: 84887153105     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch37     Document Type: Chapter

References (110)

1. Frankel, A.D. and Pabo, C.O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 55, 1189-1193.
2. Vivès, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 272, 16010-16017.
3. Joliot, A., Pernelle, C., Deagostinibazin, H., and Prochiantz, A. (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. USA, 88, 1864-1868.
4. Pooga, M., Soomets, U., Hällbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J.X., Xu, X.J., Wiesenfeld-Hallin, Z., Hökfelt, T., Bartfai, T., and Langel, Ü. (1998) Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol., 16, 857-861.
5. Schwarze, S.R., Ho, A., Vocero-Akbani, A., and Dowdy, S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
6. Richard, J.P., Melikov, K., Vivès, E., Ramos, C., Verbeure, B., Gait, M.J., Chernomordik, L.V., and Lebleu, B. (2003) Cell-penetrating peptides - a reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 278, 585-590.
7. Lundin, P., Johansson, H., Guterstam, P., Holm, T., Hansen, M., Langel, Ü., and EL Andaloussi, S. (2008) Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug. Chem., 19, 2535-2542.
8. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., and Brock, R. (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic, 8, 848-866.
9. Hansen, M., Kilk, K., and Langel, Ü . (2008) Predicting cell-penetrating peptides. Adv. Drug Deliv. Rev., 60, 572-579.
10. Derossi, D., Joliot, A., Chassaing, G., and Prochiantz, A. (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 269, 10444-10450.
11. Soomets, U., Lindgren, M., Gallet, X., Hällbrink, M., Elmquist, A., Balaspiri, L., Zorko, M., Pooga, M., Brasseur, R., and Langel, Ü. (2000) Deletion analogues of transportan. Biochim. Biophys. Acta, 1467, 165-176.
12. Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., and Sugiura, Y. (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 276, 5836-5840.
13. Morris, M.C., Depollier, J., Mery, J., Heitz, F., and Divita, G. (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol., 19, 1173-1176.
14. Morris, M.C., Vidal, P., Chaloin, L., Heitz, F., and Divita, G. (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res., 25, 2730-2736.
15. Mazel, M., Clair, P., Rousselle, C., Vidal, P., Scherrmann, J.M., Mathieu, D., and Temsamani, J. (2001) Doxorubicin-peptide conjugates overcome multidrug resistance. Anti-Cancer Drugs, 12, 107-116.
16. Rousselle, C., Clair, P., Lefauconnier, J.M., Kaczorek, M., Scherrmann, J.M., and Temsamani, J. (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol., 57, 679-686.
17. Morris, M.C., Gros, E., Aldrian-Herrada, G., Choob, M., Archdeacon, J., Heitz, F., and Divita, G. (2007) A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res., 35, e49.
18. Crombez, L., Morris, M.C., Dufort, S., Aldrian-Herrada, G., Nguyen, Q., Mc Master, G., Coll, J.L., Heitz, F., and Divita, G. (2009) Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res., 37, 4559-4569.
19. Tan, M., Lan, K.H., Yao, J., Lu, C.H., Sun, M.H., Neal, C.L., Lu, J., and Yu, D.H. (2006) Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res., 66, 3764-3772.
20. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y.X., Pestell, R.G., Albanese, C., and Darnell, J.E. (1999) Stat3 as an oncogene. Cell, 98, 295-303.
21. Jain, M., Chauhan, S.C., Singh, A.P., Venkatraman, G., Colcher, D., and Batra, S.K. (2005) Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res., 65, 7840-7846.
22. Liu, X.R., Wang, Y., Nakamura, K., Kawauchi, S., Akalin, A., Cheng, D.F., Chen, L., Rusckowski, M., and Hnatowich, D.J. (2009) Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with In-111. J. Nucl. Med., 50, 582-590.
23. Olson, E.S., Aguilera, T.A., Jiang, T., Ellies, L.G., Nguyen, Q.T., Wong, E.H., Gross, L.A., and Tsien, R.Y. (2009) In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol., 1, 382-393.
24. Myrberg, H., Zhang, L.L., Mäe, M., and Langel, Ü. (2008) Design of a tumor-homing cell-penetrating peptide. Bioconjug. Chem., 19, 70-75.
25. Chen, L. and Harrison, S. (2007) Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem. Soc. Trans., 35, 821-825.
26. Tsuji, A. (1998) P-glycoproteinmediated efflux transport of anticancer drugs at the blood-brain barrier. Ther. Drug Monit., 20, 588-590.
27. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer, 5, 275-284.
28. Aroui, S., Ram, N., Appaix, F., Ronjat, M., Kenani, A., Pirollet, F., and De Waard, M. (2009) Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm. Res., 26, 836-845.
29. Aroui, S., Brahim, S., De Waard, M., and Kenani, A. (2010) Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem. Biophys. Res. Commun., 391, 419-425.
30. Castex, C., Merida, P., Blanc, E., Clair, P., Rees, A.R., and Temsamani, J. (2004) 2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance. Anti-Cancer Drugs, 15, 609-617.
31. Nori, A., Jensen, K.D., Tijerina, M., Kopeckova, P., and Kopecek, J. (2003) Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem., 14, 44-50.
32. Dubikovskaya, E.A., Thorne, S.H., Pillow, T.H., Contag, C.H., and Wender, P.A. (2008) Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. USA, 105, 12128-12133.
33. Lindgren, M., Rosenthal-Aizman, K., Saar, K., Eiriksdóttir, E., Jiang, Y., Sassian, M., Ostlund, P., Hällbrink, M., and Langel, Ü. (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem. Pharmacol., 71, 416-425.
34. Mäe, M., Myrberg, H., El-Andaloussi, S., and Langel, Ü. (2009) Design of a tumor homing cell-penetrating peptide for drug delivery. Int. J. Pept. Res. Ther., 15, 11-15.
35. Mai, J.C., Mi, Z.B., Kim, S.H., Ng, B., and Robbins, P.D. (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res., 61, 7709-7712.
36. Guelen, L., Paterson, H., Gaken, J., Meyers, M., Farzaneh, F., and Tavassoli, M. (2004) TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene, 23, 1153-1165.
37. Marty, C., Meylan, C., Schott, H., Ballmer-Hofer, K., and Schwendener, R.A. (2004) Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci., 61, 1785-1794.
38. Tseng, Y.L., Liu, J.J., and Hong, R.L. (2002) Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and TAT: a kinetic and efficacy study. Mol. Pharmacol., 62, 864-872.
39. Torchilin, V.P., Rammohan, R., Weissig, V., and Levchenko, T.S. (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA, 98, 8786-8791.
40. Ezzat, K., El Andaloussi, S., Abdo, R., and Langel, Ü. (2010) Peptide-based matrices as drug delivery vehicles. Curr. Pharm. Des., 16, 1167-1178.
41. Ruoslahti, E., Duza, T., and Zhang, L. (2005) Vascular homing peptides with cell-penetrating properties. Curr. Pharm. Des., 11, 3655-3660.
42. Laakkonen, P., Akerman, M.E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R.M., and Ruoslahti, E. (2004) Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA, 101, 9381-9386.
43. Midgley, C.A., Desterro, J.M.P., Saville, M.K., Howard, S., Sparks, A., Hay, R.T., and Lane, D.P. (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene, 19, 2312-2323.
44. Johansson, H.J., El-Andaloussi, S., Holm, T., Mäe, M., Jänes, J., Maimets, T., and Langel, Ü. (2008) Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol. Ther., 16, 115-123.
45. Vallespi, M.G., Fernandez, J.R., Torrens, I., Garcia, I., Garay, H., Mendoza, O., Granadillo, M., Falcon, V., Acevedo, B., Ubieta, R., Guillen, G.E., and Reyes, O. (2010) Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region. J. Pept. Sci., 16, 40-47.
46. Whitehead, K., Langer, R., and Anderson, D. (2009) Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8, 129-138.
47. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392.
48. Porkka, K., Laakkonen, P., Hoffman, J.A., Bernasconi, M., and Ruoslahti, E. (2002) A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA, 99, 7444-7449.
49. Henke, E., Perk, J., Vider, J., de Candia, P., Chin, Y., Solit, D.B., Ponomarev, V., Cartegni, L., Manova, K., Rosen, N., and Benezra, R. (2008) Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat. Biotechnol., 26, 91-100.
50. Marthinet, E., Divita, G., Bernaud, J., Rigal, D., and Baggetto, L.G. (2000) Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Gene Ther., 7, 1224-1233.
51. Asai, A., Oshima, Y., Yamamoto, Y., Uochi, T., Kusaka, H., Akinaga, S., Yamashita, Y., Pongracz, K., Pruzan, R., Wunder, E., Piatyszek, M., Li, S.H., Chin, A.C., Harley, C.B., and Gryaznov, S. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res., 63, 3931-3939.
52. Davis, M.E., Zuckerman, J.E., Choi, C.H.J., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., and Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-U140.
53. Zhang, C.L., Tang, N., Liu, X.J., Liang, W., Xu, W., and Torchilin, V.P. (2006) siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release, 112, 229-239.
54. Kim, W.L., Christensen, L.V., Jo, S., Yockman, J.W., Jeong, J.H., Kim, Y.H., and Kim, S.W. (2006) Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther., 14, 343-350.
55. Eguchi, A., Meade, B.R., Chang, Y.C., Fredrickson, C.T., Willert, K., Puri, N., and Dowdy, S.F. (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol., 27, 567-U110.
56. Michiue, H., Eguchi, A., Scadeng, M., and Dowdy, S.F. (2009) Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther., 8, 2306-2313.
57. Choi, Y.S., Lee, J.Y., Suh, J.S., Kwon, Y.M., Lee, S.J., Chung, J.K., Lee, D.S., Yang, V.C., Chung, C.P., and Park, Y.J. (2010) The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 31, 1429-1443.
58. Mäe, M., El Andaloussi, S., Lundin, P., Oskolkov, N., Johansson, H.J., Guterstam, P., and Langel, Ü. (2009) A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release, 134, 221-227.
59. Lehto, T., Abes, R., Oskolkov, N., Suhorutšenko, J., Copolovici, D.M., Mäger, I., Viola, J.R., Simonson, O.E., Ezzat, K., Guterstam, P., Eriste, E., Smith, C.I.E., Lebleu, B., El Andaloussi, S., and Langel, Ü. (2010) Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J. Control. Release, 141, 42-51.
60. Torchilin, V.P., Levchenko, T.S., Rammohan, R., Volodina, N., Papahadjopoulos-Sternberg, B., and D'Souza, G.G.M. (2003) Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. USA, 100, 1972-1977.
61. Gupta, B., Levchenko, T.S., and Torchilin, V.P. (2007) TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol. Res., 16, 351-359.
62. Byrd, J.C. and Bresalier, R.S. (2004) Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev., 23, 77-99.
63. Bitler, B.G., Menzl, I., Huerta, C.L., Sands, B., Knowlton, W., Chang, A., and Schroeder, J.A. (2009) Intracellular MUC1 peptides inhibit cancer progression. Clin. Cancer Res., 15, 100-109.
64. Fulda, S., Wick, W., Weller, M., and Debatin, K.M. (2002) Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 8, 808-815.
65. Arnt, C.R., Chiorean, M.V., Heldebrant, M.V., Gores, G.J., and Kaufmann, S.H. (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem., 277, 44236-44243.
66. Vucic, D., Deshayes, K., Ackerly, H., Pisabarro, M.T., Kadkhodayan, S., Fairbrother, W.J., and Dixit, V.M. (2002) SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-LAP). J. Biol. Chem., 277, 12275-12279.
67. Yang, L.L., Mashima, T., Sato, S., Mochizuki, M., Sakamoto, H., Yamori, T., Oh-hara, T., and Tsuruo, T. (2003) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res., 63, 831-837.
68. Holinger, E.P., Chittenden, T., and Lutz, R.J. (1999) Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem., 274, 13298-13304.
69. Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S., and Korsmeyer, S.J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183-192.
70. Goldsmith, K.C., Liu, X., Dam, V., Morgan, B.T., Shabbout, M., Cnaan, A., Letai, A., Korsmeyer, S.J., and Hogarty, M.D. (2006) BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene, 25, 4525-4533.
71. Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., Grafstrom, R.C., and Wiman, K.G. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 3, 632-638.
72. Snyder, E.L. and Dowdy, S.F. (2004) Cell penetrating peptides in drug delivery. Pharm. Res., 21, 389-393.
73. Araki, D., Takayama, K., Inoue, M., Watanabe, T., Kumon, H., Futaki, S., Matsui, H., and Tomizawa, K. (2010) Cell-penetrating d-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer. Urology, 75, 813-819.
74. Kanovsky, M., Raffo, A., Drew, L., Rosal, R., Do, T., Friedman, F.K., Rubinstein, P., Visser, J., Robinson, R., Brandt-Rauf, P.W., Michl, J., Fine, R.L., and Pincus, M.R. (2001) Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl. Acad. Sci. USA, 98, 12438-12443.
75. Harbour, J.W., Worley, L., Ma, D.D., and Cohen, M. (2002) Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol., 120, 1341-1346.
76. Do, T.N., Rosal, R.V., Drew, L., Raffo, A.J., Michl, J., Pincus, M.R., Friedman, F.K., Petrylak, D.P., Cassai, N., Szmulewicz, J., Sidhu, G., Fine, R.L., and Brandt-Rauf, P.W. (2003) Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene, 22, 1431-1444.
77. Gius, D.R., Ezhevsky, S.A., Becker-Hapak, M., Nagahara, H., Wei, M.C., and Dowdy, S.F. (1999) Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res., 59, 2577-2580.
78. Fahraeus, R., Paramio, J.M., Ball, K.L., Lain, S., and Lane, D.P. (1996) Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol., 6, 84-91.
79. Frizelle, S.P., Kratzke, M.G., Carreon, R.R., Engel, S.C., Youngquist, L., Klein, M.A., Fourre, L., Shekels, L.L., and Kratzke, R.A. (2008) Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer Res., 28, 1-7.
80. Ezhevsky, S.A., Ho, A., Becker-Hapak, M., Davis, P.K., and Dowdy, S.F. (2001) Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Mol. Cell. Biol., 21, 4773-4784.
81. Hosotani, R., Miyamoto, Y., Fujimoto, K., Doi, R., Otaka, A., Fujii, N., and Imamura, M. (2002) Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res., 8, 1271-1276.
82. Baker, R.D., Howl, J., and Nicholl, I.D. (2007) A sychnological cell penetrating peptide mimic of p21WAF1/CIP1 is pro-apoptogenic. Peptides, 28, 731-740.
83. Bonfanti, M., Taverna, S., Salmona, M., Dincalci, M., and Broggini, M. (1997) p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res., 57, 1442-1446.
84. Ball, K.L., Lain, S., Fahraeus, R., Smythe, C., and Lane, D.P. (1997) Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol., 7, 71-80.
85. Chen, Y.N.P., Sharma, S.K., Ramsey, T.M., Jiang, L., Martin, M.S., Baker, K., Adams, P.D., Bair, K.W., and Kaelin, W.G. (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA, 96, 4325-4329.
86. Nagahara, H., Vocero-Akbani, A.M., Snyder, E.L., Ho, A., Latham, D.G., Lissy, N.A., Becker-Hapak, M., Ezhevsky, S.A., and Dowdy, S.F. (1998) Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med., 4, 1449-1452.
87. Parada, Y., Banerji, L., Glassford, J., Lea, N.C., Collado, M., Rivas, C., Lewis, J.L., Gordon, M.Y., Thomas, N.S., and Lam, E.W. (2001) BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J. Biol. Chem., 276, 23572-23580.
88. Minchinton, A.I. and Tannock, I.F. (2006) Drug penetration in solid tumours. Nat. Rev. Cancer, 6, 583-592.
89. Thurber, G.M., Schmidt, M.M., and Wittrup, K.D. (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev., 60, 1421-1434.
90. Aguilera, T.A., Olson, E.S., Timmers, M.M., Jiang, T., and Tsien, R.Y. (2009) Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol., 1, 371-381.
91. Kale, A.A. and Torchilin, V.P. (2007) "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J. Liposome Res., 17, 197-203.
92. Song, E.W., Zhu, P.C., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A., and Lieberman, J. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23, 709-717.
93. Essler, M. and Ruoslahti, E. (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. USA, 99, 2252-2257.
94. Trudel, D., Fradet, Y., Meyer, F., Harel, F., and Tetu, B. (2003) Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res., 63, 8511-8515.
95. Whitney, M., Crisp, J.L., Olson, E.S., Aguilera, T.A., Gross, L.A., Ellies, L.G., and Tsien, R.Y. (2010) Parallel in vivo and in vitro selection using phage display identifies protease dependent tumor targeting peptides. J. Biol. Chem., 285, 22532-22541.
96. Sethuraman, V.A. and Bae, Y.H. (2007) TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release, 118, 216-224.
97. Kale, A.A. and Torchilin, V.P. (2007) Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J. Drug Target., 15, 538-545.
98. Harada, H., Hiraoka, M., and Kizaka-Kondoh, S. (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res., 62, 2013-2018.
99. Anderson, D.C., Manger, R., Schroeder, J., Woodle, D., Barry, M., Morgan, A.C., and Fritzberg, A.R. (1993) Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides. Bioconjug. Chem., 4, 10-18.
100. Anderson, D.C., Nichols, E., Manger, R., Woodle, D., Barry, M., and Fritzberg, A.R. (1993) Tumor cell retention of antibody fab fragments is enhanced by an attached HIV TAT protein-derived peptide. Biochem. Biophys. Res. Commun., 194, 876-884.
101. Sawant, R.M., Hurley, J.P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T.S., and Torchilin, V.P. (2006) "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem., 17, 943-949.
102. Imam, S.K. (2001) Status of radioimmunotherapy in the new millennium. Cancer Biother. Radiopharm., 16, 237-256.
103. Hu, M.D., Chen, P., Wang, J., Scollard, D.A., Vallis, K.A., and Reilly, R.M. (2007) I-123-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1. Eur. J. Nucl. Med. Mol. Imaging, 34, 368-377.
104. Simberg, D., Duza, T., Park, J.H., Essler, M., Pilch, J., Zhang, L.L., Derfus, A.M., Yang, M., Hoffman, R.M., Bhatia, S., Sailor, M.J., and Ruoslahti, E. (2007) Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA, 104, 932-936.
105. Siegal, T., Horowitz, A., and Gabizon, A. (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg., 83, 1029-1037.
106. Beier, C.P., Schmid, C., Gorlia, T., Kleinletzenberger, C., Beier, D., Grauer, O., Steinbrecher, A., Hirschmann, B., Brawanski, A., Dietmaier, C., Jauch-Worley, T., Kolbl, O., Pietsch, T., Proescholdt, M., Rummele, P., Muigg, A., Stockhammer, G., Hegi, M., Bogdahn, U., and Hau, P. (2009) RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. BMC Cancer, 9, 308.
107. Dietz, G.P.H. and Bahr, M. (2005) Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res. Bull., 68, 103-114.
108. Kameyama, S., Horie, M., Kikuchi, T., Omura, T., Tadokoro, A., Takeuchi, T., Nakase, I., Sugiura, Y., and Futaki, S. (2007) Acid wash in determining cellular uptake of fab/cell-permeating peptide conjugates. Biopolymers, 88, 98-107.
109. Heitz, F., Morris, M., and Divita, G. (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol., 157, 195-206.
110. Rothbard, J., Jessop, T., Lewis, R., Murray, B., and Wender, P. (2004) Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc., 126, 9506-9507.